In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Display Of IP Strength In China: Lilly Wins Patent Dispute For Cialis Against Domestic Chinese Company

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Eli Lilly's win of the patent infringement suit in China against Jiangyin Dongfang Pharmaceutical for manufacturing tadalafil, the active ingredient in Lilly's male erectile dysfunction drug Cialis, is good news for multinational companies operating in China

You may also be interested in...



Lilly Suzhou Pharmaceutical Expands Insulin Plant

Lilly Suzhou Pharmaceutical recently held a ground-breaking ceremony for its Suzhou plant expansion project. With an investment of more than $40 million, the plant will cover an area of 50,000 square meters, 60 percent bigger than the current factory, and will be used mainly for packaging and storing insulin products. After completion of the project, both the existing and new plants will produce insulin products. The new plant will help Lilly increase its insulin production capacity to meet China's growing pharmaceutical market needs. (Click here for more - Chinese Language)

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC072529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel